| Dr Anthony I Blanchard, DPM | |
|
1555 Gary Dr, Breaux Bridge, LA 70517-3448 | |
| (337) 806-3349 | |
| (337) 909-2216 |
| Full Name | Dr Anthony I Blanchard |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 33 Years |
| Location | 1555 Gary Dr, Breaux Bridge, Louisiana |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629104344 | NPI | - | NPPES |
| 1972690 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | PD140R (Louisiana) | Primary |
| Provider Name | Anthony I Blanchard Dpm Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1255735320 PECOS PAC ID: 8921321464 Enrollment ID: O20150108000657 |
News Archive
Genetics researchers from Case Western Reserve School of Medicine have identified a novel long non-coding RNA (lncRNA), dubbed DACOR1, that has the potential to stymie the growth of tumor cells in the second-most deadly form of cancer in the U.S. — colorectal cancer.
Levine Leichtman Capital Partners, a Los Angeles-based private equity firm, announced today that Sequel Youth and Family Services, a portfolio company of Levine Leichtman Capital Partners IV, L.P., has completed the strategic acquisition of Camelot System of Care.
Metformin, a drug used to treat type-2 diabetes, could help reduce chronic inflammation in people living with HIV (PLWH) who are being treated with antiretroviral therapy (ART), according to researchers at the University of Montreal Hospital Research Centre.
WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000-2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.
BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anthony I Blanchard, DPM 232 Saint Pierre Blvd, Ste 2, Carencro, LA 70520-3914 Ph: (337) 981-4001 | Dr Anthony I Blanchard, DPM 1555 Gary Dr, Breaux Bridge, LA 70517-3448 Ph: (337) 806-3349 |
News Archive
Genetics researchers from Case Western Reserve School of Medicine have identified a novel long non-coding RNA (lncRNA), dubbed DACOR1, that has the potential to stymie the growth of tumor cells in the second-most deadly form of cancer in the U.S. — colorectal cancer.
Levine Leichtman Capital Partners, a Los Angeles-based private equity firm, announced today that Sequel Youth and Family Services, a portfolio company of Levine Leichtman Capital Partners IV, L.P., has completed the strategic acquisition of Camelot System of Care.
Metformin, a drug used to treat type-2 diabetes, could help reduce chronic inflammation in people living with HIV (PLWH) who are being treated with antiretroviral therapy (ART), according to researchers at the University of Montreal Hospital Research Centre.
WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000-2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.
BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.
› Verified 8 days ago
Anthony I Blanchard Dpm Llc Podiatrist Medicare: Medicare Enrolled Practice Location: 1555 Gary Dr, Breaux Bridge, LA 70517 Phone: 337-806-3349 Fax: 337-909-2216 |